Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Keywords
(1)
Metastatic Breast Cancer
Subscribe
Academic
Publications
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2Amplified Locally Advanced or Metastatic Breast Cancer
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2Amplified Locally Advanced or Metastatic Breast Cancer,10.1200/JCO.2007.14.0590,Journa
Edit
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2Amplified Locally Advanced or Metastatic Breast Cancer
(
Citations: 48
)
BibTex
|
RIS
|
RefWorks
Download
H. L. Gomez
,
D. C. Doval
,
P. C.-S. Ang
,
Z. Aziz
,
S. Nag
,
C. Ng
,
S. X. Franco
,
L. W. C. Chow
,
M. C. Arbushites
,
M. A. Casey
,
M. S. Berger
,
S. H. Stein
http://academic.research.microsoft.com/io.ashx?type=5&id=30792113&selfId1=0&selfId2=0&maxNumber=12&query=
Journal:
Journal of Clinical Oncology - J CLIN ONCOL
, vol. 26, no. 18, pp. 2999-3005, 2008
DOI:
10.1200/JCO.2007.14.0590
Cumulative
Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
(
jco.ascopubs.org
)
Citation Context
(11)
..., 2010), just 20% of untreated HER2-amplified metastatic patients respond to first-line lapatinib treatment in a phase II trial (
...
F Takahashi
,
et al.
Breast tumor progression induced by loss of BTG2 expression is inhibit...
..., 2006;
...
J Tanizaki
,
et al.
Roles of BIM induction and survivin downregulation in lapatinib-induce...
...In addition, progression-free survival rates were 63 and 43% at 4 and 6 months, respectively [
28
]...
April Davoli
,
et al.
Progression and treatment of HER2-positive breast cancer
...Lapatinib is a novel dual EGFR and HER-2 tyrosine kinase inhibitor that is now approved by the FDA for treatment of metastatic breast cancers with overexpression of HER-2 receptors [
20-22
]...
Roque Diaz
,
et al.
Antitumor and antiangiogenic effect of the dual EGFR and HER2 tyrosine...
...mild [
16
]. Cardiac functions have been analyzed in more than 3,000 patients treated with lapatinib in 18 Phase I–III clinical trials [17]...
Hirofumi Mukai
.
Treatment strategy for HER2-positive breast cancer
Sort by:
Citations
(48)
Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
(
Citations: 1
)
Mario Campone
,
Philippe Juin
,
Fabrice André
,
Thomas Bachelot
Journal:
Critical Reviews in Oncology Hematology - CRIT REV ONCOL HEMATOL
, vol. 78, no. 3, pp. 195-205, 2011
Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib
F Takahashi
,
N Chiba
,
K Tajima
,
T Hayashida
,
T Shimada
,
M Takahashi
,
H Moriyama
,
E Brachtel
,
E J Edelman
,
S Ramaswamy
,
S Maheswaran
Journal:
Oncogene
, vol. 30, no. 27, pp. 3084-3095, 2011
Trastuzumab et lapatinib dans la prise en charge du cancer du sein HER2 positif
S. Guiu
,
I. Adoubi
,
J. C. Kouassi Comoe
,
P. Fumoleau
,
B. Coudert
Journal:
Journal Africain Du Cancer / African Journal of Cancer
, vol. 3, no. 2, pp. 128-140, 2011
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification
J Tanizaki
,
I Okamoto
,
S Fumita
,
W Okamoto
,
K Nishio
,
K Nakagawa
Journal:
Oncogene
, vol. 30, no. 39, pp. 4097-4106, 2011
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy
Umut Kefeli
,
Ahmet Bilici
,
Bala Basak Oven Ustaalioglu
,
Aysegul Ucuncu Kefeli
,
Mahmut Emre Yildirim
,
Mesut Seker
,
Mahmut Gumus
Journal:
Archives of Gynecology and Obstetrics - ARCH GYNECOL OBSTET
, vol. 283, no. 2, pp. 405-407, 2011